The U. Nottingham spinoff company NeuPulse writes, “The clinical trial investigating the effects of median nerve stimulation on Tourette syndrome and associated symptoms has completed recruitment and all participants are now in the ‘follow-up period’, in which participants health is monitored for 6 months. The results from the trial will be published in 2023.”
such an exciting update! my son was a participant in your lab’s Median nerve stimulation clinic trial in March-April of 2022. When will the new wearable device be available in US? We are looking forward to purchase one asap.
It’s not clear to me how readily these could be made available in the U.S. But watch tics.wustl.edu for news.
We are physicians whose oldest son (24 ) has primarily Tourette’s with the usual ( OCD, ADHD, dysgraphia) secondary sequelae. Our daughter 22 has severe OCD with some tics around puberty and our youngest 19 was neurotypical until we all got pre vax severe Covid. She now has more disruptive ADHD and anxiety, it also gave her cardiac scarring costing her a D1 soccer scholarship to Duke. They are all highly functioning young adults in college or grad school. They all have more empathy and grit than average. All have found medical cannabis with intermittent NSRIs effective. We also incorporate holistic measure. Are there studies incorporating cannabis? will there be studies evaluating MNS for other basal ganglion issues like OCD?
There have been a few cannabis studies, one of the largest just recently reported. Here’s my summary of the publications: https://www.authorea.com/users/4510/articles/169839-smoke-gets-in-your-tics